Laser Diagnostic Technologies
LDT invented and commercialized a new standard for glaucoma detection with its proprietary ocular nerve fiber measurement instrument.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 23 % | 16 % | 10 % | (1 %) | 6 % | 5 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 20 % | 25 % | 25 % | 24 % | 19 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 9 % | 14 % | 15 % | 14 % | 9 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 16 % | 14 % | 15 % | 17 % | 17 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Based in San Diego, Laser Diagnostic Technologies (LDT) was a privately held medical device company focused on the eye care industry. Founded in 1991, the firm specialized in developing, manufacturing, and selling diagnostic laser equipment to detect early-stage glaucoma and macular degeneration. Key figures associated with the company included John Moore as President and CEO, and Andreas Dreher, who also served as president and chief executive at one point.
The company's business revolved around the production and sale of topographic laser scanners for medical use, specifically diagnostic scanning laser ophthalmoscopes. These devices were designed to image and measure the topography of the retina, the thickness of the nerve fiber layer, and blood flow through subretinal tissue layers. LDT's systems incorporated scanning lasers, along with software for image processing, display, and analysis. A key product was the GDx VCC, a specialized tool for glaucoma diagnosis and management that established a new standard for detection by measuring the ocular nerve fiber. This product targeted eye care professionals who needed a dedicated glaucoma tool without the broader range of features found in more multipurpose retinal imaging systems.
Financially, LDT was venture-backed, raising a notable $8.75 million in a 1999 financing round led by Vector Fund Management, with participation from existing investors like Newtek Ventures, Sigma Partners, and Sorrento Ventures. This capital was intended to expand its sales force and develop a new device for detecting age-related blindness. Over its history, the company was successful in securing government funding, receiving over $4 million in total SBIR awards for projects related to detecting macular edema and age-related macular degeneration. On October 21, 2004, Laser Diagnostic Technologies was acquired by Carl Zeiss Meditec, a German provider of eye care solutions, in a strategic move to enhance Zeiss's portfolio of glaucoma diagnostic tools.
Keywords: ophthalmic diagnostics, glaucoma detection, macular degeneration, retinal imaging, scanning laser ophthalmoscope, eye care equipment, medical devices, nerve fiber analysis, topographic laser scanner, Carl Zeiss Meditec acquisition, ocular diagnostics, retinal topography, GDx VCC, medical imaging technology, eye disease diagnosis
